Medgenome Labs Limited - Due diligence report

A 360° intelligence report on Medgenome Labs: trust score, financial health, credit view, compliance, directors, growth and distress signals…

2013-04-08 Bangalore South, Karnataka Active Unlisted Active Compliant
Share
ML Medgenome Labs Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Medgenome Labs — 360° Intelligence Report

Generated from MCA filings & public records
91/100
Trust Score
Low Risk

Medgenome Labs is assessed as Low Risk with a Trust Score of 91/100. Medgenome Labs is an active public limited indian non-government company incorporated in 2013, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 17 Jul 2026 from the latest processed filings. Medgenome Labs Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
91/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
85/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Moderate gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 1 open (3.30 cr) · 3 satisfied (55.27 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Hdfc Bank Limited3 48.0 cr
Others1 48.0 cr
Compliance Score: 85/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 1 court forum(s).
  • Delayed payments to MSME suppliers disclosed (181 disclosure(s)).
  • 6 active GST registration(s).
Legal cases on record (1)
05

Director Intelligence

Stability score: 90/100
NameDIN / PANDesignationAppointedTenureDIN status
SURYAPRAKASAM VEDAM LAKSHMI RAMPRASAD 01234567 Director 01/04/2018 6 yrs Approved
SURAJIT CHAKRABARTTY 01234567 Director 01/04/2018 6 yrs Approved
Navjeewan Jatinder Khosla 01234567 Director 01/04/2018 6 yrs Approved
PRASAD BHAGWAN SHEJALE 01234567 Director 01/04/2018 6 yrs Approved
MAHESH PRATAPNENI 01234567 Director 01/04/2018 6 yrs Approved
SURAJIT CHAKRABARTTY 01234567 Director 01/04/2018 6 yrs Approved
SHANKAR MAHADEVAPPA PRASAD 01234567 Director 01/04/2018 6 yrs Approved
Suryaprakasam Vedam Lakshmi Ramprasad 01234567 Director 01/04/2018 6 yrs Approved
  • 8 directors on the board.
  • No disqualified or deactivated DINs.
  • 3 director exit(s) in the last 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2016)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Medgenome Inc.
Subsidiaries
4
Group entities
4
Capital events
15 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Medgenome Inc. Holding Company 74.00%
Trident Diagnostics & Healthcare Private Limited Subsidiary Company 74.00%
Immucare Diagnostics Private Limited Subsidiary Company 74.00%

Key managerial personnel: SURYAPRAKASAM VEDAM LAKSHMI RAMPRASAD (CEO) · SURAJIT CHAKRABARTTY (CFO) · SURAJIT CHAKRABARTTY (CFO)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
Profit expanded 0.86 year-on-year.
Asset base grew 61% - capacity expansion.
Net margin improved to 38%.
EPFO headcount growing - hiring signal.
Operating for 13+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 8.40 Lakh.
1 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence88/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • No distress signals on file.
  • Financial filings available for verification.
Banker assessment92/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 3.30 cr already registered.
  • Compliance record supports lending.
Investor view94/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 6 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
27 Nov 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
20 Feb 2025
Director ceased
BALAMANIAMMA MADATHINKAL RAGHAVAN NAIR
25 Dec 2024
Director ceased
Navjeewan Jatinder Khosla
05 Dec 2024
Director appointed
Suryaprakasam Vedam Lakshmi Ramprasad (Ceo)
07 Nov 2024
Director appointed
Navjeewan Jatinder Khosla (Director)
23 Sep 2024
Charge satisfied
Hdfc Bank Limited
26 Mar 2024
Director ceased
SREEDHAR SANTHOSH
16 Nov 2023
Director appointed
SURYAPRAKASAM VEDAM LAKSHMI RAMPRASAD (CEO)
28 Apr 2023
Charge created
Hdfc Bank Limited - 3.30 cr
29 Nov 2022
Director ceased
AMIT KAKAR
28 Jan 2022
Securities allotted
19820 Equity Shares - 7.29 cr raised
12 Jan 2022
Securities allotted
6994 Equity Shares - 2.57 cr raised
21 Dec 2021
Securities allotted
20416 Equity Shares - 7.51 cr raised
18 Dec 2021
Securities allotted
150000 Debentures - 15.00 cr raised
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
8 active director(s) / partner(s); board looks stable and experienced.
6 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 4 subsidiary(ies) - assess on a consolidated basis.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 15 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Hemant Surgical Industries L33110MH1989PLC051133 Mumbai, Maharashtra, India
Aprameya Engineering Limited L51909GJ2021PLC128294 Ahmedabad, Gujarat, India
Sri Ramasamy Memorial Holdings Private Limited U73100TN2013PTC090981 Chennai, Tamil Nadu, India
Melam U20237TN2009PTC073126 Chennai, Tamil Nadu, India
1Mg U74140DL2015PTC279229 New Delhi, Delhi, India
Dragarwal L85110TN1994PLC027366 Chennai, Tamil Nadu, India
Focus Medisales Private Limited U04231KA1999PTC025000 Bangalore, Karnataka, India
Nephroplus L85100TG2009PLC066359 Shaikpet, Telangana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Medgenome Labs before audits and certifications: compliance score 85/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Medgenome Labs: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Medgenome Labs - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 91/100, distress signals and MSME payment-delay disclosures - know whether Medgenome Labs pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (1 case(s) on record), regulatory flags, charge documents trail and director networks for Medgenome Labs - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Medgenome Labs an active company?

Medgenome Labs has MCA status “Active” with a compliance score of 85/100 (Low Risk).

Is Medgenome Labs financially healthy?

Medgenome Labs has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.

Should I do business with Medgenome Labs?

Its overall Trust Score is 91/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Medgenome Labs?

The ultimate holding entity is Medgenome Inc.. 8 active director(s) are on record.

Does Medgenome Labs have loans or charges against its assets?

1 open charge(s) are registered against its assets, and 3 earlier charge(s) stand satisfied.

Is Medgenome Labs up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 85/100 (Low Risk).

Is it risky to lend to Medgenome Labs?

Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.